204 related articles for article (PubMed ID: 36403203)
1. A novel plant-made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the SARS-CoV-2 Omicron variant.
Jugler C; Sun H; Nguyen K; Palt R; Felder M; Steinkellner H; Chen Q
Plant Biotechnol J; 2023 Mar; 21(3):549-559. PubMed ID: 36403203
[TBL] [Abstract][Full Text] [Related]
2. Comparative Analysis of a Human Neutralizing mAb Specific for SARS-CoV-2 Spike-RBD with Cilgavimab and Tixagevimab for the Efficacy on the Omicron Variant in Neutralizing and Detection Assays.
Passariello M; Esposito S; Manna L; Rapuano Lembo R; Zollo I; Sasso E; Amato F; De Lorenzo C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373201
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
[TBL] [Abstract][Full Text] [Related]
4. Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component.
Jugler C; Sun H; Grill F; Kibler K; Esqueda A; Lai H; Li Y; Lake D; Chen Q
Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632528
[TBL] [Abstract][Full Text] [Related]
5. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
6. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
7. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.
Li R; Mor M; Ma B; Clark AE; Alter J; Werbner M; Lee JC; Leibel SL; Carlin AF; Dessau M; Gal-Tanamy M; Croker BA; Xiang Y; Freund NT
Commun Biol; 2022 Aug; 5(1):789. PubMed ID: 35931732
[TBL] [Abstract][Full Text] [Related]
8. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
10. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
12. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
13. Antibody cocktail effective against variants of SARS-CoV-2.
Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
[TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E; Saliba C; Bowen JE; Rosen LE; Culap K; Pinto D; VanBlargan LA; De Marco A; Zepeda SK; Iulio JD; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà P; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Veesler D; Snell G; Corti D
bioRxiv; 2021 Dec; ():. PubMed ID: 34931194
[TBL] [Abstract][Full Text] [Related]
15. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
Shah M; Woo HG
Front Immunol; 2021; 12():830527. PubMed ID: 35140714
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
17. An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2.
Sun C; Chi H; Yuan F; Li J; Yang J; Zheng A; Wang F; Sun L; Zhang Y; Hu P; Jiao L; Deng Y; Xie L
Sci China Life Sci; 2023 Jan; 66(1):165-179. PubMed ID: 36184693
[TBL] [Abstract][Full Text] [Related]
18. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
19. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
[TBL] [Abstract][Full Text] [Related]
20. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents.
Cao Y; Jian F; Zhang Z; Yisimayi A; Hao X; Bao L; Yuan F; Yu Y; Du S; Wang J; Xiao T; Song W; Zhang Y; Liu P; An R; Wang P; Wang Y; Yang S; Niu X; Zhang Y; Gu Q; Shao F; Hu Y; Yin W; Zheng A; Wang Y; Qin C; Jin R; Xiao J; Xie XS
Cell Rep; 2022 Dec; 41(12):111845. PubMed ID: 36493787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
